Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
57 hedge funds and large institutions have $133M invested in Unity Biotechnology in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 11 closing their positions.
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
4% more funds holding
Funds holding: 55 → 57 (+2)
0.08% more ownership
Funds ownership: 3.74% → 3.82% (+0.08%)
48% less capital invested
Capital invested by funds: $258M → $133M (-$125M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $97K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.94M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$4.24M |
| 3 |
Morgan Stanley
New York
|
+$4.23M |
| 4 |
Millennium Management
New York
|
+$969K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$567K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$7.88M |
| 2 |
PIM
Partner Investment Management
San Francisco,
California
|
-$3.43M |
| 3 |
Goldman Sachs
New York
|
-$1.96M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$686K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$474K |
UBX Hedge Fund Activity: Q1 2019 in Review
57 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q1 2019, worth a combined $133M — down 48% from $258M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new UBX positions and 11 closed out — a net gain of 2 holders — while 23 added to existing stakes and 11 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $7.94M. The largest seller was PFM Health Sciences, cutting an estimated $7.88M.
- 57 institutional investors held Unity Biotechnology (UBX) as of Q1 2019, up from 55 in Q4 2018.
- Funds reported $133M of Unity Biotechnology stock for Q1 2019, down 48% quarter-over-quarter.
- 13 funds opened new Unity Biotechnology positions in Q1 2019 and 11 closed out, a net change of +2 holders.
- The largest Unity Biotechnology buyer in Q1 2019 was Fidelity Investments, an estimated $7.94M added.
- The largest Unity Biotechnology seller in Q1 2019 was PFM Health Sciences, an estimated $7.88M sold.
Based on aggregated 13F filings for Q1 2019.